|
Abdominal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The purpose of this study was to develop a method enabling synthetic computed tomography (sCT) generation of the whole abdomen using magnetic resonance imaging (MRI) scans of pediatric patients with abdominal tumors.
|
30669135 |
2019 |
|
Acute GVH disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite advances in prevention and post transplant immuno-suppressive strategies, acute GvHD (aGvHD) remains a major cause of morbidity and mortality in children undergoing SCT.
|
18545246 |
2008 |
|
Acute GVH disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients underwent 10/10 HLA-matched peripheral blood allo-SCT (sibling donor for first and third patients and unrelated donor for the second patient; all had acute graft-versus-host disease (GVHD), and the first and third patients had chronic GVHD.
|
24994916 |
2014 |
|
Acute GVH disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The impact of KIR2DS4 alleles and the expression of KIR in the development of acute GVHD after unrelated allogeneic hematopoietic SCT.
|
20062104 |
2010 |
|
Acute GVH disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Four patients died after allo-SCT during the study period from either acute GVHD (grade IV), pneumonitis, gastrointestinal bleeding or renal insufficiency.
|
11244433 |
2001 |
|
Acute GVH disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Univariate analysis showed that MRD-WT1 negativity pre-SCT and grade <2 acute GVHD were significant prognostic factors for improved OS and DFS.
|
29096332 |
2017 |
|
Acute GVH disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In multivariate analysis, when adjusted for the European Group for Blood and Marrow Transplantation (EBMT)-Gratwohl score and other prog-nostic factors, there was an independent association between BMI-1 expression and grades 2 to 4 acute graft-versus-host disease (relative risk [RR] = 2.85; 95% confidence interval [CI], 1.3-6.4; P = .011), suggesting that BMI-1 measured prior to allo-SCT can serve as a biomarker for predicting outcome in patients with CP-CML receiving allo-SCT, and may thus contribute to better therapeutic decisions.
|
18565849 |
2008 |
|
Acute GVH disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed a retrospective analysis of HLA-G 14 bp polymorphism using a specific PCR in 47 recipients and in their respective donors, and evaluated the correlation with the incidence of aGvHD, OS and disease-free survival (DFS) after allo-SCT.
|
21399669 |
2012 |
|
Acute GVH disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Grade 2-4 acute graft-versus-host disease (GVHD) at 100-day post-DLI was higher in HID-SCT group than that in MSD-SCT group (59.5% vs. 30.8%, p = 0.05).
|
30747249 |
2019 |
|
Acute GVH disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fanconi anemia (FA) patients have an increased risk of acute GVHD (aGVHD) after hematopoietic SCT, with hypersensitivity to DNA-cross-linking agents and defective DNA repair.
|
23222379 |
2013 |
|
Acute GVH disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent insight into the pathophysiology of acute GVHD after allogeneic haematopoietic SCT has led to a growing interest in the role of natural killer (NK) cells.
|
20173792 |
2010 |
|
Acute GVH disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Single nucleotide polymorphisms (SNPs) in genes of the immune system predict for aGVHD and mortality after allo-SCT.
|
20541026 |
2010 |
|
Acute GVH disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The risk of acute graft-versus-host disease (GVHD) is significantly higher after HID-SCT versus ISD-SCT (OR = 1.88, 95% CI = 1.42-2.49, P < 0.00001), but the relapse rate is lower in HID-SCT group (OR = 0.70, 95% CI = 0.55-0.90, P = 0.005).
|
29381772 |
2018 |
|
Acute intermittent porphyria
|
0.010 |
Biomarker
|
disease |
BEFREE |
Corticosteroids increase secretin-stimulated pancreatic bicarbonate concentrations in autoimmune pancreatitis (AIP) by restoring mislocalized CFTR protein to the apical ductal membrane.
|
21844753 |
2011 |
|
Acute interstitial pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Corticosteroids increase secretin-stimulated pancreatic bicarbonate concentrations in autoimmune pancreatitis (AIP) by restoring mislocalized CFTR protein to the apical ductal membrane.
|
21844753 |
2011 |
|
Acute leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT.
|
22504932 |
2012 |
|
Acute leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
577 patients with acute leukemia or myelodysplastic syndrome receiving haplo-SCT were enrolled in the study.
|
29155367 |
2018 |
|
Acute leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Relapse after allo-SCT in patients with acute leukaemia remains a major problem.
|
19151793 |
2009 |
|
Acute leukemia in remission
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to compare the outcome of allo-SCT from T cell-replete haploidentical (Haplo) versus matched (MUD 10/10) or mismatched unrelated donor at a single HLA-locus (MMUD 9/10) for patients with acute leukemia in remission.
|
28103944 |
2017 |
|
Acute lymphocytic leukemia
|
0.050 |
Biomarker
|
disease |
BEFREE |
In ALL, risk factors for relapse were disease status different from the first complete remission (CR1) at haplo-SCT (CR2 vs CR1: HR 2.85, p = 0.011; advanced vs CR1: HR 14.28, p < 0.0001) and male donor gender (HR 3.64, p = 0.0002), while in AML, risk factors were advanced disease at haplo-SCT (advanced vs CR1: HR 3.95, p < 0.0001) and comorbidities (HCT-CI) ≥ 3 (HR 1.75, p = 0.014).
|
31272508 |
2019 |
|
Acute lymphocytic leukemia
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
|
25753432 |
2015 |
|
Acute lymphocytic leukemia
|
0.050 |
Biomarker
|
disease |
BEFREE |
Effect of donor KIR genotype on transplant outcome was evaluated in 317 children receiving a first myeloablative HSCT from an HLA-matched unrelated donor or sibling within the prospective ALL-SCT-BFM-2003 trial.
|
31089287 |
2019 |
|
Acute lymphocytic leukemia
|
0.050 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to describe changes in the HIV reservoir in a single chronically HIV-infected patient on suppressive antiretroviral therapy who underwent allo-SCT for treatment of acute lymphoblastic leukemia.
|
29182633 |
2017 |
|
Acute lymphocytic leukemia
|
0.050 |
Biomarker
|
disease |
BEFREE |
Finally, a newly diagnosed t(17;19)-ALL patient underwent allo-SCT immediately after induction of first complete remission, and the patient has survived without relapse for over 3-1/2 years after allo-SCT.
|
22743623 |
2012 |
|
Acute monocytic leukemia
|
0.090 |
Biomarker
|
disease |
BEFREE |
Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
|
27893163 |
2017 |